{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T00:24:32Z","timestamp":1724372672308},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T00:00:00Z","timestamp":1724198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T00:00:00Z","timestamp":1724198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-69587-x","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T14:57:29Z","timestamp":1724338649000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immune killer cells treatment for previously treated stage IV NSCLC patients"],"prefix":"10.1038","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct03499834","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Yen-Han","family":"Tseng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Liang","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Feng","family":"Chian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Lu","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heng-Sheng","family":"Chao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen-Liang","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wann-Cherng","family":"Perng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chin-Fu","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei-Hsing","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai-Hsiung","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-Ching","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-Jung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Jen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuh-Min","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,21]]},"reference":[{"key":"69587_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"69587_CR2","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","volume":"391","author":"C Allemani","year":"2018","unstructured":"Allemani, C. et al. Global surveillance of trends in cancer survival 2000\u201314 (CONCORD-3): Analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 391, 1023\u20131075. https:\/\/doi.org\/10.1016\/S0140-6736(17)33326-3 (2018).","journal-title":"Lancet"},{"key":"69587_CR3","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/S1470-2045(19)30329-8","volume":"20","author":"YH Luo","year":"2019","unstructured":"Luo, Y. H. et al. 5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: A prospective, observational cohort study. Lancet Oncol. 20, 1098\u20131108. https:\/\/doi.org\/10.1016\/S1470-2045(19)30329-8 (2019).","journal-title":"Lancet Oncol."},{"key":"69587_CR4","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1179\/1973947815Y.0000000027","volume":"28","author":"YH Tseng","year":"2016","unstructured":"Tseng, Y. H. et al. Efficacy of chemotherapy in epidermal growth factor receptor (EGFR) mutated metastatic pulmonary adenocarcinoma patients who had acquired resistance to first-line EGFR tyrosine kinase inhibitor (TKI). J. Chemother. 28, 50\u201358. https:\/\/doi.org\/10.1179\/1973947815Y.0000000027 (2016).","journal-title":"J. Chemother."},{"key":"69587_CR5","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1378\/chest.110.2.433","volume":"110","author":"YM Chen","year":"1996","unstructured":"Chen, Y. M., Yang, W. K., Whang-Peng, J., Kuo, B. I. & Perng, R. P. Elevation of interleukin-10 levels in malignant pleural effusion. Chest 110, 433\u2013436. https:\/\/doi.org\/10.1378\/chest.110.2.433 (1996).","journal-title":"Chest"},{"key":"69587_CR6","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1378\/chest.112.4.960","volume":"112","author":"YM Chen","year":"1997","unstructured":"Chen, Y. M. et al. Cross regulation by IL-10 and IL-2\/IL-12 of the helper T cells and the cytolytic activity of lymphocytes from malignant effusions of lung cancer patients. Chest 112, 960\u2013966. https:\/\/doi.org\/10.1378\/chest.112.4.960 (1997).","journal-title":"Chest"},{"key":"69587_CR7","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1097\/00002371-199709000-00004","volume":"20","author":"YM Chen","year":"1997","unstructured":"Chen, Y. M. et al. Restoration of the immunocompetence by IL-2 activation and TCR-CD3 engagement of the in vivo anergized tumor-specific CTL from lung cancer patients. J. Immunother. 20, 354\u2013364. https:\/\/doi.org\/10.1097\/00002371-199709000-00004 (1997).","journal-title":"J. Immunother."},{"key":"69587_CR8","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1158\/1078-0432.CCR-11-2442","volume":"18","author":"L Liu","year":"2012","unstructured":"Liu, L. et al. Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. Clin. Cancer Res. 18, 1751\u20131759. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-2442 (2012).","journal-title":"Clin. Cancer Res."},{"key":"69587_CR9","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1007\/s00262-012-1260-2","volume":"61","author":"R Li","year":"2012","unstructured":"Li, R. et al. Autologous cytokine-induced killer cell immunotherapy in lung cancer: A phase II clinical study. Cancer Immunol. Immunother. 61, 2125\u20132133. https:\/\/doi.org\/10.1007\/s00262-012-1260-2 (2012).","journal-title":"Cancer Immunol. Immunother."},{"key":"69587_CR10","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/1479-5876-4-49","volume":"4","author":"L Matera","year":"2006","unstructured":"Matera, L. et al. In vivo migration of labeled autologous natural killer cells to liver metastases in patients with colon carcinoma. J. Transl. Med. 4, 49. https:\/\/doi.org\/10.1186\/1479-5876-4-49 (2006).","journal-title":"J. Transl. Med."},{"key":"69587_CR11","doi-asserted-by":"publisher","first-page":"6155","DOI":"10.3748\/wjg.v16.i48.6155","volume":"16","author":"JT Jiang","year":"2010","unstructured":"Jiang, J. T. et al. Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients. World J. Gastroenterol. 16, 6155\u20136162. https:\/\/doi.org\/10.3748\/wjg.v16.i48.6155 (2010).","journal-title":"World J. Gastroenterol."},{"key":"69587_CR12","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.3389\/fimmu.2019.01263","volume":"10","author":"B Hervier","year":"2019","unstructured":"Hervier, B., Russick, J., Cremer, I. & Vieillard, V. NK cells in the human lungs. Front. Immunol. 10, 1263. https:\/\/doi.org\/10.3389\/fimmu.2019.01263 (2019).","journal-title":"Front. Immunol."},{"key":"69587_CR13","doi-asserted-by":"publisher","first-page":"148","DOI":"10.21037\/tlcr.2017.03.06","volume":"6","author":"JE Schoenhals","year":"2017","unstructured":"Schoenhals, J. E. et al. Uncovering the immune tumor microenvironment in non-small cell lung cancer to understand response rates to checkpoint blockade and radiation. Transl. Lung Cancer Res. 6, 148\u2013158. https:\/\/doi.org\/10.21037\/tlcr.2017.03.06 (2017).","journal-title":"Transl. Lung Cancer Res."},{"key":"69587_CR14","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1136\/jitc-2020-000668","volume":"8","author":"TH Borch","year":"2020","unstructured":"Borch, T. H. et al. Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma. J. Immunother. Cancer 8, 668. https:\/\/doi.org\/10.1136\/jitc-2020-000668 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"69587_CR15","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13046-019-1126-y","volume":"38","author":"L Fang","year":"2019","unstructured":"Fang, L. et al. Targeting late-stage non-small cell lung cancer with a combination of DNT cellular therapy and PD-1 checkpoint blockade. J. Exp. Clin. Cancer Res. 38, 123. https:\/\/doi.org\/10.1186\/s13046-019-1126-y (2019).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"69587_CR16","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.jcyt.2013.12.010","volume":"16","author":"L Durrieu","year":"2014","unstructured":"Durrieu, L. et al. Implication of different effector mechanisms by cord blood-derived and peripheral blood-derived cytokine-induced killer cells to kill precursor B acute lymphoblastic leukemia cell lines. Cytotherapy 16, 845\u2013856. https:\/\/doi.org\/10.1016\/j.jcyt.2013.12.010 (2014).","journal-title":"Cytotherapy"},{"key":"69587_CR17","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1158\/1078-0432.CCR-16-1524","volume":"23","author":"L Gammaitoni","year":"2017","unstructured":"Gammaitoni, L. et al. Cytokine-induced killer cells kill chemo-surviving melanoma cancer stem cells. Clin. Cancer Res. 23, 2277\u20132288. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1524 (2017).","journal-title":"Clin. Cancer Res."},{"key":"69587_CR18","doi-asserted-by":"publisher","first-page":"35023","DOI":"10.18632\/oncotarget.5280","volume":"6","author":"F Wei","year":"2015","unstructured":"Wei, F. et al. Cytokine-induced killer cells efficiently kill stem-like cancer cells of nasopharyngeal carcinoma via the NKG2D-ligands recognition. Oncotarget 6, 35023\u201335039. https:\/\/doi.org\/10.18632\/oncotarget.5280 (2015).","journal-title":"Oncotarget"},{"key":"69587_CR19","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/S1470-2045(12)70087-6","volume":"13","author":"VA Miller","year":"2012","unstructured":"Miller, V. A. et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b\/3 randomised trial. Lancet Oncol. 13, 528\u2013538. https:\/\/doi.org\/10.1016\/S1470-2045(12)70087-6 (2012).","journal-title":"Lancet Oncol."},{"key":"69587_CR20","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1038\/s41416-021-01353-6","volume":"124","author":"M Morotti","year":"2021","unstructured":"Morotti, M. et al. Promises and challenges of adoptive T-cell therapies for solid tumours. Br. J. Cancer 124, 1759\u20131776. https:\/\/doi.org\/10.1038\/s41416-021-01353-6 (2021).","journal-title":"Br. J. Cancer"},{"key":"69587_CR21","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1158\/1078-0432.CCR-10-2272","volume":"17","author":"J Weber","year":"2011","unstructured":"Weber, J. et al. White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: A report of the CTEP subcommittee on adoptive cell therapy. Clin. Cancer Res. 17, 1664\u20131673. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-2272 (2011).","journal-title":"Clin. Cancer Res."},{"key":"69587_CR22","doi-asserted-by":"publisher","first-page":"5233","DOI":"10.1200\/JCO.2008.16.5449","volume":"26","author":"ME Dudley","year":"2008","unstructured":"Dudley, M. E. et al. Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26, 5233\u20135239. https:\/\/doi.org\/10.1200\/JCO.2008.16.5449 (2008).","journal-title":"J. Clin. Oncol."},{"key":"69587_CR23","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1136\/jitc-2021-002449","volume":"9","author":"C Saberian","year":"2021","unstructured":"Saberian, C. et al. Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma. J. Immunother. Cancer 9, 449. https:\/\/doi.org\/10.1136\/jitc-2021-002449 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"69587_CR24","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","volume":"379","author":"L Paz-Ares","year":"2018","unstructured":"Paz-Ares, L. et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N. Engl. J. Med. 379, 2040\u20132051. https:\/\/doi.org\/10.1056\/NEJMoa1810865 (2018).","journal-title":"N. Engl. J. Med."},{"key":"69587_CR25","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi, L. et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med. 378, 2078\u20132092. https:\/\/doi.org\/10.1056\/NEJMoa1801005 (2018).","journal-title":"N. Engl. J. Med."},{"key":"69587_CR26","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jcma.2016.08.005","volume":"80","author":"YM Chen","year":"2017","unstructured":"Chen, Y. M. Immune checkpoint inhibitors for nonsmall cell lung cancer treatment. J. Chin. Med. Assoc. 80, 7\u201314. https:\/\/doi.org\/10.1016\/j.jcma.2016.08.005 (2017).","journal-title":"J. Chin. Med. Assoc."},{"key":"69587_CR27","doi-asserted-by":"publisher","first-page":"1731943","DOI":"10.1080\/2162402X.2020.1731943","volume":"9","author":"F Xu","year":"2020","unstructured":"Xu, F. et al. A TP53-associated gene signature for prediction of prognosis and therapeutic responses in lung squamous cell carcinoma. Oncoimmunology 9, 1731943. https:\/\/doi.org\/10.1080\/2162402X.2020.1731943 (2020).","journal-title":"Oncoimmunology"},{"key":"69587_CR28","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1200\/JCO.2012.45.0981","volume":"31","author":"N Katakami","year":"2013","unstructured":"Katakami, N. et al. LUX-Lung 4: A phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J. Clin. Oncol. 31, 3335\u20133341. https:\/\/doi.org\/10.1200\/JCO.2012.45.0981 (2013).","journal-title":"J. Clin. Oncol."},{"key":"69587_CR29","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1093\/annonc\/mdv597","volume":"27","author":"M Schuler","year":"2016","unstructured":"Schuler, M. et al. Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib\/gefitinib and afatinib: Phase III randomized LUX-Lung 5 trial. Ann. Oncol. 27, 417\u2013423. https:\/\/doi.org\/10.1093\/annonc\/mdv597 (2016).","journal-title":"Ann. Oncol."},{"key":"69587_CR30","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1172\/JCI132712","volume":"130","author":"M Lin","year":"2020","unstructured":"Lin, M. et al. Pembrolizumab plus allogeneic NK cells in advanced non-small cell lung cancer patients. J. Clin. Investig. 130, 2560\u20132569. https:\/\/doi.org\/10.1172\/JCI132712 (2020).","journal-title":"J. Clin. Investig."},{"key":"69587_CR31","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1038\/bjc.2013.585","volume":"109","author":"LM Wintner","year":"2013","unstructured":"Wintner, L. M. et al. Quality of life during chemotherapy in lung cancer patients: Results across different treatment lines. Br. J. Cancer 109, 2301\u20132308. https:\/\/doi.org\/10.1038\/bjc.2013.585 (2013).","journal-title":"Br. J. Cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-69587-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-69587-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-69587-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T15:17:09Z","timestamp":1724339829000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-69587-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,21]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["69587"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-69587-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,21]]},"assertion":[{"value":"10 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19374"}}